טוען...
Daratumumab in untreated newly diagnosed multiple myeloma
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies. Daratumumab, a fully human monoclonal antibody targeting CD38, has shown clinical efficacy in relapsed/refractory multiple myeloma both as monothe...
שמור ב:
| הוצא לאור ב: | Ther Adv Hematol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6928545/ https://ncbi.nlm.nih.gov/pubmed/31903177 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620719894871 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|